Black Di­a­mond spins out an­ti­body work in­to new biotech with $30M from Ver­sant, NEA

Black Di­a­mond Ther­a­peu­tics con­tin­ues to nar­row its fo­cus.

Mon­day morn­ing, the can­cer com­pa­ny an­nounced that it was spin­ning out its an­ti­body work in­to a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER